Program
QLS5133
A development code. Also written as “QLS5133; Lenvatinib mesylate”, “QLS5133; QL2107; Lenvatinib mesylate” and “QLS5133; Bevacizumab”.
Its studies are mostly in Carcinoma, Renal Cell, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 22 open or running | phase 2since Jul 1, 2025 | Jul 1, 2025 | Jul 2027phase 2 · NCT07061639 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07061639 · 212 planned · China
- Nov 6, 2026Phase 2 study in Carcinoma, Renal CellNCT07933419 · 558 planned · China
Ahead
- Jul 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07061639
- Nov 15, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT07933419
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933419Carcinoma, Renal Cell · China | 2 | Not yet recruiting | Nov 15, 2027 | 558 |
| NCT07061639Advanced Solid Tumors · China | 2 | Not yet recruiting | Jul 2027 | 212 |
How it is read
Names in the registry
- “QLS5133; Lenvatinib mesylate”, 1 entry
- “QLS5133; QL2107; Lenvatinib mesylate”, 1 entry
- “QLS5133; Bevacizumab”, 1 entry
- “QLS5133; Platinum; Bevacizumab”, 1 entry
- “QLS5133; Olaparib; Bevacizumab”, 1 entry
Codes read as this program: QLS5133.
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.